Results 221 to 230 of about 114,702 (262)
Some of the next articles are maybe not open access.
Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials
Current Hematologic Malignancy Reports, 2013BTK is a cytoplasmic, non-receptor tyrosine kinase that transmits signals from a variety of cell-surface molecules, including the B-cell receptor (BCR) and tissue homing receptors. Genetic BTK deletion causes B-cell immunodeficiency in humans and mice, making this kinase an attractive therapeutic target for B-cell disorders. The BTK inhibitor ibrutinib
openaire +2 more sources
Development of Bruton’s Tyrosine Kinase Inhibitors for Rheumatoid Arthritis
Current Medicinal Chemistry, 2019Rheumatoid Arthritis (RA) is a chronic autoimmune disease and becomes one of the major causes of disability and work force loss. The presence of abnormal B cell and autoantibodies produced by most RA patients, primarily ACPA and RF, indicate that the function of B cell was involved in the development of RA disease.
Jiahui, Lv +5 more
openaire +2 more sources
Small-Molecule Inhibitors of Bruton’s Tyrosine Kinase
2017Bruton’s tyrosine kinase has emerged as a promising drug target for multiple diseases, particularly hematopoietic malignancies. As a result of intensive efforts, many inhibitors have been developed to target BTK. Among them, considerable progress has been made in covalent inhibitors. In this chapter, example compounds will be discussed to highlight our
Yingying Zuo, Zhengying Pan
openaire +1 more source
Journal of Medicinal Chemistry, 2020
Autoreactive B cell-derived antibodies form immune-complexes that likely play a pathogenic role in autoimmune diseases. In Systemic Lupus Erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory cytokine ...
Bin Ma +23 more
semanticscholar +1 more source
Autoreactive B cell-derived antibodies form immune-complexes that likely play a pathogenic role in autoimmune diseases. In Systemic Lupus Erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory cytokine ...
Bin Ma +23 more
semanticscholar +1 more source
Next-Generation Bruton Tyrosine Kinase Inhibitors
Journal of Clinical Oncology, 2020Deborah M, Stephens, John C, Byrd
openaire +2 more sources
Bruton's tyrosine kinase inhibitors in B‐cell non‐Hodgkin's lymphomas
Clinical Pharmacology & Therapeutics, 2015The B‐cell receptor pathway (BCR) is aberrantly activated in select B‐cell malignancies. This knowledge has allowed for the development of inhibitors of different crucial steps of this pathway. Bruton's tyrosine kinase (BTK) is a key component of BCR signaling and functions as an important regulator of multiple cell functions including differentiation,
L, Alinari, C, Quinion, K A, Blum
openaire +2 more sources
Radiation Recall Dermatitis With Bruton Tyrosine Kinase Inhibitor Therapy
JAMA DermatologyThis case report describes a woman in her 70s with a history of breast cancer and chronic lymphocytic leukemia who presented with a painful rash of the bilateral chest extending onto the flanks.
Ahmad, Rajeh +2 more
openaire +2 more sources
Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations
Current Opinion in NeurologyPurpose of review Despite availability of high-efficacy therapies for multiple sclerosis (MS), many patients experience significant disability worsening due to limited effects of currently available drugs on central nervous system (CNS)-compartmentalized inflammation.
Julia, Krämer, Heinz, Wiendl
openaire +2 more sources